MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to these inhibitors. PD‐L1 (CD274) expression, one of the factors th...

Descripción completa

Detalles Bibliográficos
Autores principales: Stutvoet, Thijs S, Kol, Arjan, de Vries, Elisabeth GE, de Bruyn, Marco, Fehrmann, Rudolf SN, Terwisscha van Scheltinga, Anton GT, de Jong, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767771/
https://www.ncbi.nlm.nih.gov/pubmed/30972766
http://dx.doi.org/10.1002/path.5280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767771/
https://www.ncbi.nlm.nih.gov/pubmed/30972766
http://dx.doi.org/10.1002/path.5280

Ejemplares similares